Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 known ✓ | P22894 | 2/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.46 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.45 |
| ▸ | ANPEP | P15144 | 3/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.44 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | CIT | O14578 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6941161 | 1.00 | SLC7A5 (0.54) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL7422736 | 1.00 | SLC7A5 (0.54) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL2715188 | 0.98 | SLC7A5 (0.56) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL836565 | 0.98 | SLC7A5 (0.56) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL1174387 | 0.98 | SLC7A5 (0.56) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL23056597 | 0.84 | SLC7A5 (0.47) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL8624053 | 0.80 | SLC7A5 (0.52) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL8624056 | 0.80 | SLC7A5 (0.52) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL8768451 | 0.80 | SLC7A5 (0.52) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL23422900 | 0.79 | SLC7A5 (0.42) | SLC7A5AAK1LARS1ANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110753690-B | Pyridine derivatives | 豪夫迈·罗氏有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-116102449-A | Phenyl derivatives as cannabinoid receptor 2 agonists | 豪夫迈·罗氏有限公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-3642200-B1 | PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-03 | — | — | EP | disclosed |
| CN-108349901-B | Phenyl derivatives as cannabinoid receptor 2 agonists | 豪夫迈·罗氏有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11339120-B2 | Phenyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220064178-A1 | PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-03-03 | — | — | US | disclosed |
| US-11117903-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210171441-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200239490-A1 | PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3642200-A1 | PYRIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-9290451-B2 | — | — | 2016-03-22 | — | — | US | disclosed |
| EP-2718266-A1 | PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | US | disclosed |
| WO-2012168350-A1 | PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-5672583-A | Carboxy-peptidyl derivatives as antidegenerative active agents | MERCK & CO., INC. (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0671911-A4 | CARBOXY-PEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS. | MERCK & CO INC (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0671911-A1 | CARBOXY-PEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO. INC. (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994012169-A1 | CARBOXY-PEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO., INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-4568666-A | COLLAGENASE INHIBITORS, ANTIARTJRITIC AGENTS | G. D. SEARLE & CO. (US) | 1986-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171441-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | CNR2, CNR1, GPR18 | MMP8 4835/4885SLC7A5 4164/4885AAK1 681/4885 |
| US-20220064178-A1 | PYRIDINE DERIVATIVES | NDUFS6, NDUFS3, CYP11B2 | MMP8 4537/4885SLC7A5 4036/4885AAK1 2559/4885 |
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | MMP8 4634/4885SLC7A5 2449/4885AAK1 2948/4885 |
| US-20200239490-A1 | PYRIDINE DERIVATIVES | NDUFS6, NDUFS3, CYP11B2 | MMP8 4537/4885SLC7A5 4036/4885AAK1 2559/4885 |
| US-11117903-B2 | Pyridine derivatives | NDUFS6, NDUFS3, CYP11B2 | MMP8 4537/4885SLC7A5 4036/4885AAK1 2559/4885 |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | CNR2, CNR1, GPR174 | MMP8 4865/4885SLC7A5 3557/4885AAK1 919/4885 |
| US-11339120-B2 | Phenyl derivatives as cannabinoid receptor 2 agonists | CNR2, CNR1, GPR18 | MMP8 4835/4885SLC7A5 4164/4885AAK1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.